FTSE 100 news / Companies and sectors / GSK / HUTCHMED licensing deal with GSK closes
HUTCHMED licensing deal with GSK closes
+6.3 strongly positive
HUTCHMED closed its exclusive licence deal with GSK for a KRAS-EGFR antibody conjugate.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| Investing.com India | 1 | +7.0 |
| Quiver Quantitative | 1 | +6.7 |
| Pluang | 1 | +6.7 |
| Yahoo Finance | 1 | +6.7 |
| BigGo Finance | 1 | +5.8 |
| Kalkine Media | 1 | +5.0 |
Day by day
Wednesday 21 October 2026
HUTCHMED closed its exclusive licence deal with GSK for a KRAS-EGFR antibody conjugate.
- +7.0 HUTCHMED closes $110M licensing deal with GSK for cancer therapy
Closed $110M licence deal adds cancer pipeline asset - +6.7 HUTCHMED Announces Closing of Exclusive Global License Agreement with GSK for HMPL-A830
Licence agreement closing adds oncology asset - +6.7 HUTCHMED closes exclusive license deal with GSK for KRAS-EGFR antibody therapy outside China.
Exclusive licence closed for antibody therapy outside China - +6.7 HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
Licence closing gives GSK rights outside China - +5.8 Hutchmed's KRAS-EGFR Conjugate Therapy Goes Global as $110 Million Upfront Payment Nears
Licensing deal for KRAS-EGFR therapy extends GSK oncology pipeline
Thursday 15 October 2026
Kalkine Media looks at HUTCHMED after a licensing deal with GSK and a US filing.
- +5.0 Why Is HUTCHMED (LSE:HCM) Stock In Focus After A Licensing Deal With FTSE 100 Drugmaker GSK And A US Filing?
Licensing deal with HUTCHMED involving GSK